AEON Biopharma And Priveterra Acquisition Corp. Announce Filing Of S-4 Registration Statement For Proposed Business Combination

AEON Biopharma, Inc. ("AEON" or the "Company"), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp., ((PMGM) (Priveterra), a special purpose acquisition company, today announced the filing of Form S-4 Registration Statement ("S-4") with the U.S. Securities and Exchange Commission ("SEC") regarding the recently announced business combination between the two companies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221226005060/en/

To learn more about AEON and the development of its uniquely positioned therapeutic neurotoxin, visit www.aeonbiopharma.com.